Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains

Expert Review of Vaccines

Volumn 10, Issue 5, 2011, Pages 635-644

  Verdijk, Pauline ^a   Rots, Nynke Y ^a   Bakker, Wilfried A M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

clinical trial; inactivated poliomyelitis vaccine; polio eradication; poliomyelitis; Sabin IPV; vaccine development

Indexed keywords

POLIOMYELITIS VACCINE;

DIARRHEA; DRUG SAFETY; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALAISE; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; VIRUS STRAIN; VOMITING;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HUMANS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL;

EID: 79957602607     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.51     Document Type: Review

References (78)

1. Salk JE. A concept of the mechanism of immunity for preventing paralysis in poliomyelitis. Ann. NY Acad. Sci. 61(4), 1023-1036; discussion, 1036-1028 (1955).
2. Salk JE. Vaccination against paralytic poliomyelitis performance and prospects. Am. J. Public Health Nations Health 45(5 Pt 1), 575-596 (1955).
3. Ehrenfeld E, Modlin J, Chumakov K. Future of polio vaccines. Expert Rev. Vaccines 8(7), 899-905 (2009).
4. Salk J, van Wezel AL, Stoeckel P et al. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. Dev. Biol. Stand. 47, 181-198 (1981). (Pubitemid 11186759)
5. Minor P. Gaps in scientific knowledge for the post eradication world. Biologicals 34(2), 167-170 (2006). (Pubitemid 43765780)
6. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis. 151(3), 420-436 (1985). (Pubitemid 15103791)
7. WHO. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper - recommendations. Vaccine 28(43), 6943-6944 (2010).
8. Agol VI. Vaccine-derived polioviruses. Biologicals 34(2), 103-108 (2006). (Pubitemid 43765784)
9. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccinederived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 59, 587-635 (2005). (Pubitemid 41507443)
10. Jenkins HE, Aylward RB, Gasasira A et al. Implications of a circulating vaccinederived poliovirus in Nigeria. N. Engl. J. Med. 362(25), 2360-2369 (2010).
11. Dragunsky EM, Ivanov AP, Wells VR et al. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J. Infect. Dis. 190(8), 1404-1412 (2004). (Pubitemid 39332179)
12. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27(20), 2649-2652 (2009).
13. Chumakov K, Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin. Infect. Dis. 47(12), 1587-1592 (2008).
14. Heinsbroek E, Ruitenberg EJ. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine 28(22), 3778-3783 (2010).
15. Doi Y, Abe S, Yamamoto H et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev. Biol. (Basel) 105, 163-169 (2001).
16. Simizu B, Abe S, Yamamoto H et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 34(2), 151-154 (2006).
17. Aylward BR, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D. Risk management in a polio-free world. Risk Anal. 26(6), 1441-1448 (2006). (Pubitemid 44952469)
18. Heymann DL, Sutter RW, Aylward RB. A global call for new polio vaccines. Nature 434(7034), 699-700 (2005). (Pubitemid 40558352)
19. Duchene M, Peetermans J, D'Hondt E, Harford N, Fabry L, Stephenne J. Production of poliovirus vaccines: past, present, and future. Viral Immunol. 3(4), 243-272 (1990).
20. Minor PD. The molecular biology of poliovaccines. J. Gen. Virol. 73(Pt 12), 3065-3077 (1992). (Pubitemid 23014156)
21. Tebbens RJ, Pallansch MA, Kew OM et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 26(6), 1471-1505 (2006). (Pubitemid 44952471)
22. Fine PE, Ritchie S. Perspective: determinants of the severity of poliovirus outbreaks in the post eradication era. Risk Anal. 26(6), 1533-1540 (2006). (Pubitemid 44952473)
23. Thomassen YE, van Sprang ENM, van der Pol LA, Bakker WAM. Multivariate data analysis on historical IPV production data for better process understanding and future improvements. Biotechnol. Bioeng. 107(1), 96-104 (2010).
24. Westdijk J, Brugmans D, Martin J et al. Characterization and standardization of sabin based inactivated polio vaccine. Proposal for a new antigen unit for inactivated polio vaccines. Vaccine 29(18), 3390-3397 (2011).
25. Bakker WAM, Thomassen YE, van der Pol LA. Scale-down approach for animal-free polio vaccine production. In: Cells and Culture; Proceedings of the 20th ESACT meeting, June 17-20, 2007, Dresden, Germany. Noll T (Ed.). Springer, Berlin, Germany, 541-550 (2010).
26. Bevilacqua JM, Young L, Chiu SW, Sparkes JD, Kreeftenberg JG. Rat immunogenicity assay of inactivated poliovirus. Dev. Biol. Stand. 86, 121-127 (1996).
27. Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from liveattenuated Sabin strains. Vaccine 25(41), 7041-7046 (2007). (Pubitemid 47470098)
28. Kersten G, Hazendonk T, Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 17(15-16), 2059-2066 (1999). (Pubitemid 29172378)
29. Dragunsky EM, Ivanov AP, Abe S et al. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine. J. Infect. Dis. 194(6), 804-807 (2006). (Pubitemid 44344128)
30. Murph JR, Grose C, McAndrew P et al. Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr. Infect. Dis. J. 7(11), 760-765 (1988). (Pubitemid 18266221)
31. Simizu B. Development of Sabin-inactivated poliovirus vaccine. Presented at: Polio Immunization: Moving Forward. NIH, Bethesda, USA, September 19-20 (2007).
32. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO collaborative study group on oral and inactivated poliovirus vaccines. Bull. World Health Organ. 74(3), 253-268 (1996).
33. Asturias EJ, Dueger EL, Omer SB et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J. Infect. Dis. 196(5), 692-698 (2007). (Pubitemid 47293850)
34. Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N. Engl. J. Med. 356(15), 1536-1544 (2007).
35. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol. Rec. 78(28), 241-250 (2003).
36. Plotkin SA, Vidor E. Chapter 25: Poliovirus vaccine-inactivated. In: Vaccines Expert Consult. Saunders, Philadelphia, PA, USA (2008).
37. Haastrup E, Thierry-Carstensen B, Jensen AM, Stellfeld M, Heilmann C. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in Vero-cells. Vaccine 22(8), 958-962 (2004). (Pubitemid 38221088)
38. Rumke H, Labadie J, Elzinga-Gholizadea N, Mensinga T. IPV-Vero vaccine induces a strong booster reaction and is well tolerated in adults. Scand J. Infect. Dis. 30(5), 535-538 (1998). (Pubitemid 29054368)
39. Salk J, Salk D. Control of influenza and poliomyelitis with killed virus vaccines. Science 195(4281), 834-847 (1977). (Pubitemid 8048141)
40. Salk J. Immune response and minimum requirement for immunity to disease. Scand. J. Infect. Dis. Suppl. 36, 65-67 (1982). (Pubitemid 13125854)
41. Bottiger M. Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 8(5), 443-445 (1990). (Pubitemid 20332852)
42. Conyn-Van Spaendonck MA, de Melker HE, Abbink F, Elzinga-Gholizadea N, Kimman TG, van Loon T. Immunity to poliomyelitis in The Netherlands. Am. J. Epidemiol. 153(3), 207-214 (2001). (Pubitemid 32958642)
43. Grimprel E, von Sonnenburg F, Sanger R, Abitbol V, Wolter JM, Schuerman LM. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 23(28), 3657-3667 (2005). (Pubitemid 40692411)
44. Rumke HC, Oostvogel PM, Van Steenis G, Van Loon AM. Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiol. Infect. 115(2), 289-298 (1995).
45. Martin J, Crossland G, Wood DJ, Minor PD. Characterization of formaldehydeinactivated poliovirus preparations made from live-attenuated strains. J. Gen. Virol. 84(Pt 7), 1781-1788 (2003). (Pubitemid 36805913)
46. Rezapkin G, Martin J, Chumakov K. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. Biologicals 33(1), 29-39 (2005). (Pubitemid 40248764)
47. Salk J, Stoeckel P, van Wezel AL, Lapinleimu K, van Steenis G. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen. Ann. Clin. Res. 14(5-6), 204-212 (1982). (Pubitemid 13172727)
48. Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J. Infect. Dis. 162(6), 1291-1297 (1990).
49. McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am. J. Epidemiol. 128(3), 615-628 (1988).
50. Nirmal S, Cherian T, Samuel BU, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 16(9-10), 928-931 (1998). (Pubitemid 28276003)
51. Simasathien S, Migasena S, Beuvery C et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scand. J. Infect. Dis. 26(6), 731-738 (1994).
52. Krishnan R, Jadhav M, John TJ. Efficacy of inactivated poliovirus vaccine in India. Bull. World Health Organ. 61(4), 689-692 (1983). (Pubitemid 13010187)
53. Sormunen H, Stenvik M, Eskola J, Hovi T. Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. J. Med. Virol. 63(4), 305-310 (2001). (Pubitemid 32195395)
54. Taranger J, Trollfors B, Knutsson N, Sundh V, Lagergard T, Ostergaard E. Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 18(9-10), 884-891 (2000).
55. Perkins FT, Yetts R, Gaisford W. Serological response of infants to poliomyelitis vaccine. Br. Med. J. 2(5088), 68-71 (1958).
56. Simoes EA, Padmini B, Steinhoff MC, Jadhav M, John TJ. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am. J. Dis. Child. 139(10), 977-980 (1985). (Pubitemid 16236492)
57. Dayan GH, Thorley M, Yamamura Y et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J. Infect. Dis. 195(1), 12-20 (2007). (Pubitemid 44958222)
58. Kok PW, Leeuwenburg J, Tukei P et al. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull. World Health Organ. 70(1), 93-103 (1992).
59. Swartz TA, Handsher R, Stoeckel P et al. Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur. J. Epidemiol. 5(2), 143-145 (1989). (Pubitemid 19162197)
60. Krishnan R, Jadhav M, Selvakumar R, John TJ. Immune response of infants in tropics to injectable polio vaccine. Br. Med. J. (Clin. Res. Ed.) 284(6310), 164 (1982). (Pubitemid 12171758)
61. Simoes EA, John TJ. The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. J. Biol. Stand. 14(2), 127-131 (1986). (Pubitemid 16065702)
62. Salk J. One-dose immunization against paralytic poliomyelitis using a noninfectious vaccine. Rev. Infect. Dis. 6(Suppl. 2), S444-S450 (1984).
63. Clark TW, Pareek M, Hoschler K et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361(25), 2424-2435 (2009).
64. Schwarz TF, Spaczynski M, Schneider A et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 27(4), 581-587 (2009).
65. Vesikari T, Karvonen A, Tilman S et al. Immunogenicity and safety of MF59- adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 126(4), e762-e770 (2010).
66. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol. Oncol. 109(Suppl. 2), S15-S21 (2008). (Pubitemid 351636109)
67. Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine 29(4), 644-649 (2011).
68. Yang C, Shi H, Zhou J, Liang Y, Xu H. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine 27(47), 6558-6563 (2009).
69. Ivanov AP, Dragunsky EM, Chumakov KM. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J. Infect. Dis. 193(4), 598-600 (2006). (Pubitemid 43202752)
70. Salk J, Cohen H, Fillastre C et al. Killed poliovirus antigen titration in humans. Dev. Biol. Stand. 41, 119-132 (1978). (Pubitemid 9104695)
71. Resik S, Tejeda A, Lago PM et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J. Infect. Dis. 201(9), 1344-1352 (2010).
72. Mohammed AJ, AlAwaidy S, Bawikar S et al. Fractional doses of inactivated poliovirus vaccine in Oman. N. Engl. J. Med. 362(25), 2351-2359 (2010).
73. Burns CC, Campagnoli R, Shaw J, Vincent A, Jorba J, Kew O. Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons. J. Virol. 83(19), 9957-9969 (2009).
74. Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 297(5583), 1016-1018 (2002). (Pubitemid 34856035)
75. Macadam AJ, Ferguson G, Stone DM et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol. 80(17), 8653-8663 (2006). (Pubitemid 44384875)
76. Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14(2), 154-161 (2008). (Pubitemid 351214560)
77. Collett MS, Neyts J, Modlin JF. A case for developing antiviral drugs against polio. Antiviral Res. 79(3), 179-187 (2008).
78. Norder H, De Palma AM, Selisko B et al. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res. 89(3), 204-218 (2011).